Trial Details
UNKNOWNBasic Information
| Clinical ID | c1472 |
|---|---|
| Identifier | NCT04990258 |
| Trial Title | A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Inflammatory Bowel Diseases |
| Interventions | DRUG: Subcutaneous infliximab CT-P13 Remsima®SC |
Participant Information
| Sponsor | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives |
|---|---|
| City | Grenoble |
| Country/Region | France |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | OBSERVATIONAL |
|---|---|
| Phase | NULL |
Time Information
| Start Date | 2021-09-06 |
|---|---|
| Primary Completion Date | 2024-06-30 |
| Completion Date | 2024-09-30 |